| 摘要 |
The present disclosure relates to a pharmaceutical product for the treatment of a proliferative disease, comprising the combination of an antibody, or an antigen-binding portion thereof, that specifically binds to human CD40; and a PD-L1 antibody; and optionally a 3 rd component which comprises as an active ingredient a cytokine inhibitor. |
